As the world population nears the 8 billion mark, Novartis is celebrating the delivery of 1 billion antimalarial treatments since 1999. That is the equivalent of 1 in 8 people living on our planet!

Learn how we’re working with partners like the International Agency for the Prevention of Blindness to eliminate preventable blindness.

Standing by people with sickle cell disease and their families

As a company, we stand up for greater inclusion of LGBTI people because when each of us feels included, we all benefit.

Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.

European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.

The RUXCOVID clinical trial highlights the Novartis commitment to leverage our expertise and resources to support the global response to the COVID-19 pandemic.

A recent summit explored how technological advances could impact patient care.

The Novartis Foundation is launching a blood pressure management program in Vietnam as part of its larger effort to combat the rise of chronic diseases in urban areas of developing countries.